← All trials
NCT01687218
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2013
- Primary completion
- May 26, 2015
- Completion date
- May 26, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 195
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- CONRADLead sponsor
- University of PittsburghStudy chair
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Institute of Mental Health (NIMH)Collaborator
- National Institutes of Health (NIH)Collaborator
- Asociación Civil Impacta Salud y Educación, PeruStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.